Skip to main content
SpringerLink
Log in

Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions

  • ORIGINAL ARTICLE
  • Published:
International Journal of Legal Medicine Aims and scope Submit manuscript

Abstract

Venlafaxine (VEN) is an antidepressant found to possess a higher fatal toxicity index (FTI, i.e., deaths in proportion to consumption) than other newer antidepressants and selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to elucidate using post-mortem cases whether the apparent high toxicity of VEN is associated with adverse drug interactions, pharmacogenetic factors and/or the manner of death. Within a 2-year period, a comprehensive post-mortem database and death certificates were searched for cases with laboratory findings of VEN, findings of other drugs, associated background information and the cause and manner of death. In 123 cases, the concentrations of VEN and its two metabolites, O-desmethylvenlafaxine (O-VEN) and N-desmethylvenlafaxine (N-VEN), and the CYP2D6 genotype were determined in post-mortem blood. The median concentrations of VEN, O-VEN and N-VEN were 560, 420 and 49 µg/l, respectively. A prominent feature of the VEN-positive cases was the high abundance of interacting drugs (46%), being more common with higher VEN concentrations. Compared to other common antidepressants, VEN-positive cases showed the highest suicide frequency, but also the proportion of suicidal VEN poisonings of all suicides was substantially higher than that of mirtazapine or SSRIs. Relative CYP2D6 activity did not predispose to high VEN concentrations, and the frequency of the extreme phenotypes followed the general population. In conclusion, the high suicide potential of VEN in combination with the high prevalence of drugs causing adverse interactions could be the reason for the observed high FTI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Holliday SM, Benfield P (1995) Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49:280–294

    Article  PubMed  CAS  Google Scholar 

  2. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM (1996) Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41:149–156

    Article  PubMed  CAS  Google Scholar 

  3. Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (1999) O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480–490

    Article  PubMed  CAS  Google Scholar 

  4. Ereshefsky L, Dugan D (2000) Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 12(Suppl 1):30–44

    Article  PubMed  Google Scholar 

  5. Eap CB, Lessard E, Baumann P, Brawand-Amey M, O’Hara G, Turgeon J (2003) Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 13:39–47

    Article  PubMed  CAS  Google Scholar 

  6. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A (2009) Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 19:170–179

    Article  PubMed  CAS  Google Scholar 

  7. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229–243

    Article  PubMed  CAS  Google Scholar 

  8. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23–37

    Article  PubMed  CAS  Google Scholar 

  9. Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H (2008) Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol 64:483–487

    Article  PubMed  CAS  Google Scholar 

  10. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442–473

    Article  PubMed  CAS  Google Scholar 

  11. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S (2006) CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31:493–502

    Article  PubMed  CAS  Google Scholar 

  12. Langford NJ, Martin U, Ruprah M, Ferner RE (2002) Alternative venlafaxine kinetics in overdose. J Clin Pharm Ther 27:465–467

    Article  PubMed  CAS  Google Scholar 

  13. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J (1999) Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9:435–443

    Article  PubMed  CAS  Google Scholar 

  14. Kawanishi C, Lundgren S, Agren H, Bertilsson L (2004) Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 59:803–807

    Article  PubMed  CAS  Google Scholar 

  15. Whyte EM, Romkes M, Mulsant BH, Kirshne MA, Begley AE, Reynolds CF 3rd, Pollock BG (2006) CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry 21:542–549

    Article  PubMed  Google Scholar 

  16. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE (2005) Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 27:478–483

    Article  PubMed  Google Scholar 

  17. Öhberg A, Vuori E, Ojanpera I, Lonngvist J (1996) Alcohol and drugs in suicides. Br J Psychiatry 169:75–80

    Article  PubMed  Google Scholar 

  18. Koski A, Vuori E, Ojanpera I (2005) Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. Int J Leg Med 119:344–348

    Article  Google Scholar 

  19. Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH (2004) Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 184:41–47

    Article  PubMed  Google Scholar 

  20. Morgan O, Griffiths C, Baker A, Majeed A (2004) Fatal toxicity of antidepressants in England and Wales, 1993-2002. Health Stat Q 23:18–24

    PubMed  Google Scholar 

  21. Buckley NA, McManus PR (2002) Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325:1332–1333

    Article  PubMed  Google Scholar 

  22. Bosse GM, Spiller HA, Collins AM (2008) A fatal case of venlafaxine overdose. J Med Toxicol 4:18–20

    Article  PubMed  Google Scholar 

  23. Howell C, Wilson AD, Waring WS (2007) Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 64:192–197

    Article  PubMed  CAS  Google Scholar 

  24. Megarbane B, Bloch V, Deye N, Baud FJ (2007) Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose. Intensive Care Med 33:195–196, author reply 197

    Article  PubMed  Google Scholar 

  25. Roxanas M, Hibbert E, Field M (2007) Venlafaxine hyponatraemia: incidence, mechanism and management. Aust N Z J Psychiatry 41:411–418

    Article  PubMed  Google Scholar 

  26. Egger C, Muehlbacher M, Nickel M, Geretsegger C, Stuppaeck C (2006) A case of recurrent hyponatremia induced by venlafaxine. J Clin Psychopharmacol 26:439

    Article  PubMed  Google Scholar 

  27. Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN (2004) Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 42:67–71

    Article  PubMed  CAS  Google Scholar 

  28. Whyte IM, Dawson AH, Buckley NA (2003) Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96:369–374

    Article  PubMed  CAS  Google Scholar 

  29. Wilson AD, Howell C, Waring WS (2007) Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series. J Toxicol Sci 32:97–101

    Article  PubMed  CAS  Google Scholar 

  30. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE, Lohr KN (2008) Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 31:851–865

    Article  PubMed  CAS  Google Scholar 

  31. Weinmann S, Becker T, Koesters M (2008) Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl) 196:511–520

    Article  CAS  Google Scholar 

  32. Stahl SM, Grady MM, Moret C, Briley M (2005) SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10:732–747

    PubMed  Google Scholar 

  33. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J (2008) Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 299:901–913

    Article  PubMed  CAS  Google Scholar 

  34. Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N (2009) The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci Doi:. doi:10.1007/s00406-008-0849-0

    Google Scholar 

  35. Mines D, Hill D, Yu H, Novelli L (2005) Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 14:367–372

    Article  PubMed  Google Scholar 

  36. Rasanen I, Kontinen I, Nokua J, Ojanpera I, Vuori E (2003) Precise gas chromatography with retention time locking in comprehensive toxicological screening for drugs in blood. J Chromatogr B Analyt Technol Biomed Life Sci 788:243–250

    Article  PubMed  CAS  Google Scholar 

  37. Sistonen J, Fuselli S, Levo A, Sajantila A (2005) CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem 51:1291–1295

    Article  PubMed  CAS  Google Scholar 

  38. Strandell J, Bate A, Lindquist M, Edwards IR, Swedish, Finnish, Interaction X-referencing Drug-drug Interaction Database (SFINX Group) (2008) Drug-drug interactions—a preventable patient safety issue? Br J Clin Pharmacol 65:144–146

    Article  PubMed  Google Scholar 

  39. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234–242

    Article  PubMed  CAS  Google Scholar 

  40. Moffat AC, Osselton MD, Widdop B (eds) (2004) Clarke’s analysis of drugs and poisons, 3rd edn. UK, Pharmaceutical Press, London

    Google Scholar 

  41. Vuori E, Ojanperä I, Nokua J, Ojansivu RL (2006) Oikeuskemiallisesti todetut myrkytyskuolemat Suomessa vuosina 2002-2004. Suomen lääkärilehti (Finnish Medical Journal) 61:2339–2344, in Finnish, English summary: Fatal poisonings in Finland 2002-2004

    Google Scholar 

  42. Reis M, Aamo T, Ahlner J, Druid H (2007) Reference concentrations of antidepressants A compilation of postmortem and therapeutic levels. J Anal Toxicol 31:254–264

    PubMed  CAS  Google Scholar 

  43. Goeringer KE, McIntyre IM, Drummer OH (2001) Postmortem tissue concentrations of venlafaxine. Forensic Sci Int 121:70–75

    Article  PubMed  CAS  Google Scholar 

  44. Jaffe PD, Batziris HP, van der Hoeven P, DeSilva D, McIntyre IM (1999) A study involving venlafaxine overdoses: comparison of fatal and therapeutic concentrations in postmortem specimens. J Forensic Sci 44:193–196

    PubMed  CAS  Google Scholar 

  45. Launiainen T, Vuori E, Ojanpera I (2009) Prevalence of adverse drug combinations in a large post-mortem toxicology database. Int J Leg Med 123:109–115

    Article  Google Scholar 

  46. Deshauer D (2007) Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose. CMAJ 176:39–40

    PubMed  Google Scholar 

  47. Saarikoski ST, Sata F, Husgafvel-Pursiainen K, Rautalahti M, Haukka J, Impivaara O, Jarvisalo J, Vainio H, Hirvonen A (2000) CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. Pharmacogenetics 10:5–10

    Article  PubMed  CAS  Google Scholar 

  48. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526

    Article  PubMed  CAS  Google Scholar 

  49. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516–520

    PubMed  CAS  Google Scholar 

  50. Løvlie R, Daly AK, Matre GE, Molven A, Steen VM (2001) Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11:45–55

    Article  PubMed  Google Scholar 

  51. Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E (2006) The complexity of active metabolites in therapeutic drug monitoring of psychotrophic drugs. Pharmacopsychiatry 39:121–127

    Article  PubMed  CAS  Google Scholar 

  52. Flanagan RJ (2008) Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol 23(Suppl 1):43–51

    Article  PubMed  Google Scholar 

  53. Rodda KE, Drummer OH (2006) The redistribution of selected psychiatric drugs in post-mortem cases. Forensic Sci Int 164:235–239

    Article  PubMed  CAS  Google Scholar 

  54. Levine B, Jenkins AJ, Queen M, Jufer R, Smialek JE (1996) Distribution of venlafaxine in three postmortem cases. J Anal Toxicol 20:502–505

    PubMed  CAS  Google Scholar 

  55. Reis M, Lundmark J, Björk H, Bengtsson F (2002) Therapeutic drug monitoring of racemic venlafaxine and its metabolites in an everyday clinical setting. Ther Drug Monit 24:545–553

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Dr. Johanna Sistonen for her help with the genotyping.

Author information

Authors and Affiliations

  1. Department of Forensic Medicine, University of Helsinki, P.O. Box 40, FI-00014, Helsinki, Finland

    Terhi Launiainen, Ilpo Rasanen, Erkki Vuori & Ilkka Ojanperä

Authors
  1. Terhi Launiainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilpo Rasanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erkki Vuori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilkka Ojanperä
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Terhi Launiainen.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM Table 1

(PDF 4 kb)

ESM Table 2

(PDF 4 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Launiainen, T., Rasanen, I., Vuori, E. et al. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med 125, 349–358 (2011). https://doi.org/10.1007/s00414-010-0461-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00414-010-0461-5

Keywords

Search

Navigation